Suppr超能文献

预测重型再生障碍性贫血对免疫抑制联合艾曲泊帕的反应。

Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag.

机构信息

Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health.

Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.

出版信息

Haematologica. 2022 Jan 1;107(1):126-133. doi: 10.3324/haematol.2021.278413.

Abstract

Pretreatment blood counts, particularly an absolute reticulocyte count ≥25×109/L, correlate with response to immunosuppressive therapy in severe aplastic anemia. In recent trials, eltrombopag combined with standard immunosuppressive therapy yielded superior responses than those to immunosuppressive therapy alone. Our single institution retrospective study aimed to elucidate whether historical predictors of response to immunosuppressive therapy alone were also associated with response to immunosuppressive therapy plus eltrombopag. We sought correlations of blood counts, thrombopoietin levels and the presence of paroxysmal nocturnal hemoglobinuria clones with both overall and complete responses in 416 patients with severe aplastic anemia, aged 2-82 years (median, 30 years), initially treated with immunosuppressive therapy plus eltrombopag between 2012 and 2019 (n=176) or with immunosuppressive therapy alone between 1999 and 2010 (n=240). Compared to non-responders, patients in the group of overall responders to immunosuppressive therapy plus eltrombopag had significantly higher pretreatment absolute reticulocyte counts, higher neutrophil counts and reduced thrombopoietin levels, as also observed for the group treated with immunosuppressive therapy alone. Addition of eltrombopag markedly improved the overall response in subjects with an absolute reticulocyte count between 10-30×109/L from 60% (54 of 90) to 91% (62 of 68). Absolute lymphocyte count correlated with complete response in the groups treated with immunosuppressive therapy with or without eltrombopag, especially in adolescents aged ≥10 years and adults, but the correlation was reversed in younger children. Platelet count and the presence of a paroxysmal nocturnal hemoglobinuria clone did not correlate with responses to immunosuppressive therapy. Blood counts remain the best predictors of response to nontransplant therapies in severe aplastic anemia. Addition of eltrombopag to immunosuppressive therapy shifted patients with a lower absolute reticulocyte count into a better prognostic category.

摘要

预处理时的血液计数,尤其是绝对网织红细胞计数≥25×109/L,与重型再生障碍性贫血对免疫抑制治疗的反应相关。在最近的试验中,艾曲波帕联合标准免疫抑制治疗比单独免疫抑制治疗的反应更优。我们的单中心回顾性研究旨在阐明,单独接受免疫抑制治疗的反应的历史预测因子是否也与免疫抑制治疗加艾曲波帕的反应相关。我们在 416 名年龄为 2-82 岁(中位年龄 30 岁)的重型再生障碍性贫血患者中寻找血液计数、血小板生成素水平和阵发性睡眠性血红蛋白尿克隆的存在与整体反应和完全反应的相关性,这些患者最初于 2012 年至 2019 年期间接受免疫抑制治疗加艾曲波帕治疗(n=176)或 1999 年至 2010 年期间接受单独免疫抑制治疗(n=240)。与无反应者相比,接受免疫抑制治疗加艾曲波帕治疗的整体反应者的预处理绝对网织红细胞计数明显更高,中性粒细胞计数更高,血小板生成素水平更低,这与单独接受免疫抑制治疗的患者组也观察到的情况相同。在绝对网织红细胞计数在 10-30×109/L 之间的患者中,添加艾曲波帕可使免疫抑制治疗的总体反应明显改善,从 60%(54/90)增加到 91%(62/68)。在接受免疫抑制治疗加或不加艾曲波帕治疗的患者组中,淋巴细胞绝对计数与完全反应相关,尤其是在年龄≥10 岁的青少年和成年人中,但在年龄较小的儿童中则相反。血小板计数和阵发性睡眠性血红蛋白尿克隆的存在与免疫抑制治疗的反应无关。血液计数仍然是重型再生障碍性贫血非移植治疗反应的最佳预测因子。在免疫抑制治疗中添加艾曲波帕可将绝对网织红细胞计数较低的患者转移到预后较好的类别。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/095e/8719075/57766758a4b1/107126.fig1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验